Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Amazon Explores AI Content Marketplace With Media Publishers 
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
AST SpaceMobile Joins MSCI ACWI Index as Largest New Addition, Boosting Market Visibility 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
DUBLIN, Ireland, April 09, 2018 -- Horizon Pharma plc (Nasdaq:HZNP) announced today that its first-quarter financial results will be released on Wednesday, May 9, 2018. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results.
The live webcast and replay may be accessed at http://ir.horizon-pharma.com. Please connect to the Company's website at least 15 minutes before the live webcast to ensure adequate time for any software download that may be needed to access the webcast.
About Horizon Pharma plc
Horizon Pharma plc is focused on researching, developing and commercializing innovative medicines that address unmet treatment needs for rare and rheumatic diseases. By fostering a growing pipeline of medicines in development and exploring all potential uses for currently marketed medicines, we strive to make a powerful difference for patients, their caregivers and physicians. For us, it’s personal: by living up to our own potential, we are helping others live up to theirs. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter, like us on Facebook or explore career opportunities on LinkedIn.
Contacts:
Investors:
Tina Ventura
Senior Vice President,
Investor Relations
[email protected]
Ruth Venning
Executive Director,
Investor Relations
[email protected]
U.S. Media:
Geoff Curtis
Senior Vice President,
Corporate Affairs & Chief Communications Officer
[email protected]
Ireland Media:
Ray Gordon
Gordon MRM
[email protected]
